A Phase I Study of Immune Checkpoint Inhibition (Anti-CTLA4 and/or Anti-PD-L1) in Combination With Radiation Therapy in Patients With Unresectable and Non-metastatic Pancreatic Cancer

Trial Profile

A Phase I Study of Immune Checkpoint Inhibition (Anti-CTLA4 and/or Anti-PD-L1) in Combination With Radiation Therapy in Patients With Unresectable and Non-metastatic Pancreatic Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Feb 2020.
    • 11 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2019.
    • 07 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top